← Back to Search

COPE2Thrive Program for Adolescent Mental Health

Phase 1
Recruiting
Led By Miriam Tepper, MD
Research Sponsored by Cambridge Health Alliance
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months or time to completion of the cope2t intervention
Awards & highlights
No Placebo-Only Group

Summary

This trial uses an online tool to identify mental health issues early and offers support to help high-risk youth from diverse backgrounds build resilience. It aims to provide activities that help manage stress, especially for those who often face barriers to getting mental health care.

Who is the study for?
This trial is for high school students in certain areas who speak English, Haitian Creole, Portuguese, or Spanish and show moderate symptoms of mental health issues. It excludes seniors, those already in therapy, or urgently suicidal individuals.
What is being tested?
The study tests COPE2Thrive—a preventive intervention against usual care—to improve adolescent wellbeing and resilience in diverse communities during a healthcare crisis.
What are the potential side effects?
Since the interventions are non-medical (COPE2Thrive program and usual care), typical drug side effects aren't expected. However, there may be emotional discomfort from discussing personal issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months or time to completion of the cope2t intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months or time to completion of the cope2t intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Kiddie Computerized Adaptive Testing Self Report (K-CAT-S)
Secondary study objectives
Kiddie Computerized Adaptive Testing Parent Report(K-CAT-P)
Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P)
Weiss Functional Impairment Rating Scale - Self Report (WFIRS-S)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: R34#1 Aim 2 COPE2Thrive InterventionExperimental Treatment1 Intervention
Randomly clustered youth who have completed the screening will be randomized to receive a resilience based digital intervention, COPE2Thrive.
Group II: Control armActive Control1 Intervention
The comparator arm is treatment as usual. For each monthly crossover, 12 students in a cluster are eligible to receive C2T in a stepped wedge study design. Student outcomes prior to receiving C2T will be compared to outcomes after receiving C2T.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Resilience-based prevention programs for adolescent wellbeing focus on early assessment and preventive measures to promote mental health resilience. These programs typically employ cognitive-behavioral strategies, psychoeducation, and skills training to enhance coping mechanisms and emotional regulation. By identifying at-risk youth early and equipping them with tools to manage stress and build resilience, these interventions aim to prevent the onset of mental health issues. This proactive approach is essential for adolescent wellbeing as it helps address potential problems before they escalate, fostering a supportive environment that promotes long-term mental health and stability.
Employing a sequential multiple assignment randomized trial (SMART) to evaluate the impact of brief risk and protective factor prevention interventions for American Indian Youth Suicide.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Cambridge Health AllianceLead Sponsor
62 Previous Clinical Trials
22,501 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,913 Previous Clinical Trials
2,738,427 Total Patients Enrolled
Miriam Tepper, MDPrincipal InvestigatorCambridge Health Alliance

Media Library

Cope2Thrive Clinical Trial Eligibility Overview. Trial Name: NCT04935710 — Phase 1
Adolescent Wellbeing Research Study Groups: R34#1 Aim 2 COPE2Thrive Intervention, Control arm
Adolescent Wellbeing Clinical Trial 2023: Cope2Thrive Highlights & Side Effects. Trial Name: NCT04935710 — Phase 1
Cope2Thrive 2023 Treatment Timeline for Medical Study. Trial Name: NCT04935710 — Phase 1
~9 spots leftby Feb 2025